MIDDLE EAST HEALTHCARE COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.5 SAR | -1.09% |
|
-5.53% | +2.49% |
| 04-04 | Middle East Healthcare Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-31 | Middle East Healthcare Co. Reports Higher FY23 Profit, Revenue | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 32.23 and 23.8 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.55 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +2.49% | 2.22B | - | ||
| -17.07% | 16.85B | B+ | ||
| +3.60% | 12.34B | B | ||
| +5.64% | 11.77B | B+ | ||
| +5.10% | 10.28B | B+ | ||
| +25.36% | 8.38B | B | ||
| -0.68% | 7.88B | A- | ||
| +22.18% | 7.29B | D | ||
| +5.77% | 6.75B | B- | ||
| +52.00% | 4.69B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4009 Stock
- Ratings Middle East Healthcare Company
